FDA Import Alert for inadequate Inspection Management
An Indian drug manufacturing facility received a Warning Letter and an import alert because FDA investigators were detained from doing their job properly.
It started with a strike. According the Warning Letter, the company informed FDA that "workers and staff have gone on strike" and "blocked off the entrance of the facility" one week before the scheduled inspection. As a result, the FDA cancelled this pre-announced inspection. And the company kept on communicating that the strike is ongoing. However, "FDA obtained evidence" that the company was manufacturing during this time period.
When FDA finally inspected the facility a few months later, the company didn't really support the inspection process adequately:
- Doors were locked
- Batch records were not provided
- Lights were off (and the investigator "had to perform parts of the walkthrough in the dark, using a flashlight")
As a result, FDA placed the company on Import Alert 66-40 and on Import Alert 99-32.
Find out more details in the FDA Warning Letter an Vikshara Trading & Investments Ltd.
Related GMP News
24.07.2024FDA Warning Letter to a Manufacturer of an Athlete Muscle Maintenance Creme
24.07.2024FDA describes detailed CAPA Procedure in Warning Letter
17.07.2024Congressional Scrutiny on FDA's Foreign Inspection Program puts Pressure on Agency
19.06.2024More FDA Inspections again - also in the EU?
12.06.2024GMP Problems with critical Medicinal Products - what now?
15.05.2024Lack of Quality Oversight: EU Non-Compliance Report issued to Omeprazole Manufacturer